Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment [Seeking Alpha]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Seeking Alpha
REC-4881's Phase 1/2 data show a median polyp reduction of 43%, but mean efficacy matches Celebrex, undermining premium pricing or clinical differentiation. Durability and real-world adoption are questionable, with RXRX management shifting focus to niche populations and external controls for pivotal studies. RXRX continues significant cash burn, with Q3 net loss of $162.25M and operational trends suggesting further downside despite a $785M cash runway. demaerre/iStock via Getty Images Introduction Recursion Pharmaceuticals, Inc.'s ( RXRX ) stock is down 18% since my rating downgrade to “Sell” in October. I ascertained that Recursion was “just a well-funded R&D platform with unproven translation.” The company was still looking for its first This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 WeeksGlobeNewswire
- Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]Yahoo! Finance
- Lightning Round: Recursion Pharmaceuticals and NuScale Power [CNBC]CNBC
- Cramer's Lightning Round: Recursion Pharmaceuticals ‘has been horrendous' [CNBC]CNBC
- Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025GlobeNewswire
RXRX
Earnings
- 11/5/25 - Beat
RXRX
Sec Filings
- 12/8/25 - Form 8-K
- 12/5/25 - Form 4
- 12/4/25 - Form 4
- RXRX's page on the SEC website